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Genovefa A. Papanicolaou1Vancomycin-resistant enterococci (VRE) are common pathogens of bloodstream infections in the peritrans-
plantation period. Linezolid is approved by the FDA for treating VRE infections, but has been associated with
low rates of hematologic toxicity in the general population; thus, there are concerns about its potential mye-
lotoxicity in the allogeneic hematopoietic stem cell transplantation (HSCT) setting.We examined the impact
of linezolid treatment on the times to neutrophil and platelet engraftment in 33 patients who underwent
HSCT. In this retrospective case-controlled study conducted from 2000 through 2007, cases received $ 7
consecutive days of linezolid therapy, starting before day18 post-HSCT. Controls received$ 7 consecutive
days of vancomycin therapy before day18 and were matched to cases by age and conditioning regimen. The
cumulative incidence function was used to estimate the probabilities for the times to neutrophil and platelet
engraftment. A competing-risk regression model was used to determine whether times to engraftment dif-
fered for cases and controls. A total of 33 cases were compared with 33 controls. The median duration of
treatment after stem cell infusion was 14 days (range, 7 to 34 days) for linezolid and 16 days (range, 8 to 33
days) for vancomycin. The rates of neutrophil and platelet engraftment were similar between the cases and
controls. After adjusting for baseline characteristics, no difference in the times to neutrophil or platelet en-
graftment was seen between the 2 groups. Our findings demonstrate no adverse effect on the times to neu-
trophil or platelet engraftment with linezolid use. Larger prospective studies are needed to fully determine
the hematologic safety of linezolid in patients undergoing HSCT.
Biol Blood Marrow Transplant 15: 1337-1341 (2009)  2009 American Society for Blood and Marrow TransplantationKEY WORDS: Linezolid, Engraftment, Safety, Platelet, Neutrophil, Allogeneic stem cell transplantationINTRODUCTION
Linezolid (Zyvox) is indicated for the treatment of
infections caused by resistant gram-positive organisms,
including vancomycin-resistant enterococci (VRE) [1].
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selection in HSCT is the potential for myelotoxicity,
particularly in the periengraftment period. Linezolid
has been associated with a low rate of reversible cytope-
nias in the general population [5-10]. The exact mecha-
nism of linezolid-induced myelosuppression is not
known, but may be related to inhibition of mitochon-
drial protein synthesis [7]. In Phase III trials, the fre-
quency of thrombocytopenia was 2.4% in patients
receiving linezolid versus 1.5% in comparator groups
[1]. In clinical trials of nosocomial pneumonia, the rates
of thrombocytopenia were comparable in patients re-
ceiving linezolid and those receiving vancomycin [9].
In a randomized trial of linezolid in febrile, neutropenic
patients with cancer, the rates of hematologic adverse
events were similar to those seen in patients receiving
vancomycin [11]. The hematologic safety of linezolid
in the HSCT setting has not yet been studied, however.
We conducted a retrospective study to assess the impact
of linezolid on the times to neutrophil and platelet
engraftment in patients undergoing HSCT.1337
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Study Patients
The Memorial Sloan-Kettering Cancer Center
(MSKCC) Institutional Review Board approved this
study. A total of 596 adult and 229 pediatric patients
underwent allogeneic HSCT at MSKCC between
January 1, 2000 and December 31, 2007. Cases were
defined as patients who started linezolid before day
18 after HSCT and received linezolid for$ 7 consec-
utive days. Control patients were matched to cases by
age (1/-5 years) and type of conditioning regimen
(total body irradiation [TBI]-containing or all chemo-
therapy); they started vancomycin before day 18 and
received vancomycin for $ 7 consecutive days. Labo-
ratory values, drug administration, and adverse events
were extracted from chart review. The notes of the
attending physician around the time of linezolid dis-
continuation were reviewed for clinical assessment of
myelosuppression.
All cases and controls received a myeloablative
(MA) conditioning regimen. Regimens based on frac-
tionatedTBI included thiotepa and cyclophosphamide
(Cy) or thiotepa and fludarabine (Flu); all-chemother-
apy regimens included busulfan (Bu) and Cy or Bu and
melphalan (Mel). Recipients of unmodified HSCT
received standard graft-versus-host disease (GVHD)
prophylaxis; recipients of T cell–depleted grafts did
not receive additional GVHD immunoprophylaxis.
Standard antimicrobial prophylaxis included fluco-
nazole and acyclovir, starting at cytoreduction. Tri-
methoprim-sulfamethoxazole or pentamidine (in cases
of sulfa allergy) was given from days 27 though 23
pre-HSCT for Pneumocystis prophylaxis. The initial
antibiotic regimen for fever and neutropenia was piper-
acillin/tazobactamplus amikacin in adults and cefepime
plus amikacin in children. Initiation of vancomycin or
linezolid was at the discretion of the treating physician.
Vancomycin was added empirically if there were con-
cerns about catheter-related infection, to treatmicrobi-
ologically documented infection, or in patients with
persistent fever andneutropeniawithnopathogen iden-
tified. Linezolidwas initiated empirically in persistently
febrile and neutropenic patients who had a documented
VRE infection or a history of VRE colonization or
infection.Definitions
Time to Neutrophil Engraftment
ANC500was calculated as thenumberof days from
the date of stem cell infusion to the first date of an ab-
solute neutrophil count (ANC) . 500/mm3 for 3 con-
secutive days. ANC 1000 was calculated as the number
of days from the date of stem cell infusion to the first
date of an ANC . 1000/mm3 for 3 consecutive days.Time to Platelet Engraftment
PLT 20 was calculated as the number of days from
the date of stem cell infusion to the first date of a plate-
let count (PLT). 20,000/mm3 for 3 consecutive days
and no platelet transfusion for 7 days from the last
PLT transfusion. PLT 50 was calculated as the num-
ber of days from the date of stem cell infusion to the
first date of a PLT . 50,000/mm3 for 3 consecutive
days and no platelet transfusion for 7 days from the
last PLT transfusion.
Statistical Analysis
The frequency distribution of the patient charac-
teristics, stratified by drug treatment, was calculated.
Fisher’s exact test and Wilcoxon’s rank-sum test
were used to examine covariate differences between
cases (linezolid) and controls (vancomycin). The
cumulative incidence function was used to estimate
the probabilities for times to ANC 500 or ANC 1000
and times to PLT 20 or PLT 50. Gray’s test was
used to determine whether the cumulative incidence
curves differed by the drug administered. Because
drug administration was started at varying time points
post-HSCT, a landmark analysis was used to assess the
effect of the drugs on engraftment. The landmark for
the analysis was day 18 post-HSCT. Patients who
had engrafted or died before the landmark day were ex-
cluded. A competing-risk regressionmodel was used to
determine whether the incidence functions differed by
drug after adjusting for baseline factors. The hazard
ratios, 95% confidence intervals (CIs), and P values
from this model were calculated. The statistical pack-
ages SAS (version 9.1) and R (version 2.3.1) were used
to compute the test statistics and build the competing-
risk regression models.RESULTS
During the study period, 33 patients treated with
linezolid met the case definition criteria. Each case
was matched to a control (vancomycin group). The
mean age at transplantation was 45.1 years for the van-
comycin group and 44.8 years for the linezolid group.
Baseline characteristics were similar in the 2 groups
(Table 1). Themedian number of days on drug therapy
after HSCT was 14 days (range, 7 to 34 days) in the
linezolid group and 16 days (range, 8 to 33 days) in
the vancomycin group. The median total duration of
therapy was 15 days (range, 7 to 39 days) in the line-
zolid group and 21 days (range, 9 to 45 days) in the
vancomycin group. Fifty eight percent and 85% of
patients were recieving linezolid and vancomycin,
respectively by day 15 of patients receiving.
First, the effect of linezolid on the time to ANC
500 was examined (Figure 1). The proportion of
patients who achieved ANC 500 on each day after
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Figure 1. Cumulative incidence for ANC 500 by treatment group. The
solid line represents linezolid; the dashed line, vancomycin.
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Figure 2. Cumulative incidence for PLT 20 by treatment group. The
solid line represents linezolid; the dashed line, vancomycin.
Table 1. Demographics and baseline characteristics of cases
and controls
Vancomycin
(n 5 33)
Linezolid
(n 5 33) P Value
Age at transplantation,
years, mean
(standard deviation)
45.1 (17.6) 44.8 (17.6) .88
Sex 1.0
Female 12 (50.0) 12 (50.0)
Male 21 (50.0) 21(50.0)
Donor type .62
Matched related sibling 18 (54.6) 15 (45.5)
All other 15 (45.5) 18 (54.5)
Stem cell source .78
Bone marrow 10 (55.6) 8 (44.4)
Peripheral blood 23 (47.9) 25 (52.1)
Conditioning regimen 1.0
All chemotherapy 19 (48.7) 20 (51.3)
TBI-based 14 (51.9) 13 (48.2)
Days on drug,
median (range)*
16 (8-33) 14 (7-34) .25
Days to ANC 500, median
(range)
12 (8-27) 11 (8-33) .47
TBI indicates total body irradiation. Values in parentheses are percent-
ages unless stated otherwise.
*Number of days post stem cell infusion.
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.23). Similar results were found for the time to ANC
1000 (P 5 .18).
Next, the effect of linezolid on the time to PLT
20 was examined. Figure 2 shows the proportion of
cases and controls achieving PLT 20 on each day after
the landmark day. The proportion of patients achiev-
ing PLT 20 was similar in the 2 groups (P5 .87). Sim-
ilar results were found for the time to PLT50 (P5 .93).
A competing-risk regression model was used to
adjust for potential imbalances in transplantation-
related characteristics between cases and controls.
Table 2 characterizes the effect of treatment on the
times to ANC 500 and PLT 20 after adjusting sepa-
rately for each characteristic. These adjusted models
further suggest that linezolid had no negative impact
on the time to neutrophil or platelet engraftment com-
pared with vancomycin.
All patients treated with linezolid achieved en-
graftment. Linezolid was discontinued before comple-
tion of treatment in 3 patients (9.6%) because of the
treating physicians’ concerns about possible myelo-
suppression. All of these 3 patients were being treated
for VRE bloodstream infection and were receiving
concomitant medications associated with cytopenias
in addition to linezolid. Two of the 3 patients received
only 7 days of linezolid therapy and recovered their
counts within 7 days of stopping the drug. The third
patient underwent HSCT for myelodysplastic syn-
drome (MDS) and received 18 days of linezolid ther-
apy before developing secondary graft failure. The
treating physician attributed the graft failure to stro-
mal dysfunction, not to linezolid. Of note, this patient
did not respond to a boost infusion of peripheral bloodstem cells (PBSCs) from the same donor. Four of 33
patients (12.1%) treated with vancomycin did not
achieve neutrophil engraftment. One of these patients
had primary graft failure, and the other 3 died before
engraftment.DISCUSSION
Linezolid is currently approved by the FDA for the
treatment of infections resulting from VRE [1]. In the
HSCT setting, the potential for myelosuppression is
an important factor influencing physicians’ choice of
anti-infective agents. Because of rising rates of VRE
bloodstream infections in patients undergoing HSCT,
linezolid often is prescribed in the early periengraft-
ment period. Emerging resistance of VRE to linezolid
has been reported [12]. Alternative antibiotics with in
vitro activity against VRE include daptomycin (Cubi-
cin) and tigecycline (Tygacil); however, neither of these
Table 2. Competing-risk regression model on the effect of
treatment drug on engraftment
Adjusting
Variables
Hazard Ratio of Linezolid
versus Vancomycin
(95% Confidence Interval) P Value
ANC 500
Age at HSCT 1.4 (0.9-2.2) .13
Sex 1.4 (0.9-2.2) .12
Total days of exposure to
treatment drugs before baseline*
1.3 (0.88-2.10) .16
Stem cell source 1.5 (0.9-2.3) .06
Donor matched type 1.4 (0.9-2.2) .11
PLT 20
Age at HSCT 1.0 (0.6-1.7) .90
Sex 1.0 (0.6-1.6) .97
Total days of exposure to
treatment drugs before baseline*
1.0 (0.5-1.8) .87
Stem cell source 1.0 (0.5-1.7) 1.0
Donor type 1.0 (0.6-1.7) .88
HSCT indicates hematopoietic stem cell transplantation. Each row rep-
resents a competing-risk model testing the effect of treatment drug on
achieving neutrophil engraftment (ANC 500) and platelet engraftment
(PLT 20) after adjusting for the corresponding baseline variable. The P
value corresponds to the significance of the drug effect.
*Baseline was defined as day +8 post-HSCT.
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VRE infections [13,14]. The emergence of daptomycin
resistance in VRE during treatment with daptomycin
has been reported [15]. Furthermore, the empiric use
of daptomycin in critically ill HSCT recipients is re-
stricted by the drug’s lack of activity against pulmonary
infections [13], whereas tigecycline achieves low con-
centrations in the serum, a concern when treating
bloodstream infections [14]. Of the remaining options,
quinupristin/dalfopristin (Synercid) is FDA-approved
for the treatment of infections resulting from VRE,
but is active only against vancomycin-resistant Entero-
coccus faecium. The utility of this agent is further limited
by high rates of infusion-related reactions, arthralgias,
and myalgias [16]. Despite these limiting factors, how-
ever, physicians often prefer these other therapeutic
options because of concerns about possible myelosup-
pression because of linezolid in the periengraftment
period.
In this study, we examined the impact of linezolid
on the times to neutrophil and platelet engraftment
in 33 consecutive HSCT recipients treated with line-
zolid and 33 HSCT recipients treated with vancomy-
cin. Because drug exposure relative to stem cell
infusion was variable, we performed a landmark analy-
sis using day18 post-HSCT as the landmark. Of note,
58% and 85% of patients were already on linezolid and
vancomycin respectively by day15. The times to ANC
500 and PLT 20 were similar in the cases and controls,
as were the times to ANC 1000 and PLT 50. This sug-
gests that linezolid did not hinder further recovery of
neutrophils or platelets after the minimum milestones
of ANC 500 and PLT 20 were achieved.
Because of the retrospective nature of the present
study, we cannot control for a selection bias in thepatients who received linezolid. During the period
2000-2005, linezolid was the only option available for
treating VRE infections. After the approval of dapto-
mycin and reports of successful treatment of VRE in-
fections with this agent, physicians may have
preferentially used daptomycin in patients at the great-
est risk for myelosuppression. There was also an inher-
ent imbalance in the types of infection between the 2
treatment groups. More than 50% of the patients
treated with linezolid had VRE bloodstream infection,
which has been associated with increased rates of graft
failure and poor clinical outcome inHSCT [3, 17]. De-
spite this adverse prognostic factor in the linezolid-
treated group, we did not find any adverse effect on
the time to neutrophil or platelet engraftment relative
to the controls.
Various host- and transplantation-related charac-
teristics are known to influence the times to neutrophil
and platelet engraftment. To adjust for any potential
imbalances in these factors between cases and controls,
we compared treatment with linezolid and treatment
with vancomycin after adjusting for each baseline
factor. The competing-risk regression model further
supports no adverse effect of treatment with linezolid
compared with vancomycin on neutrophil and platelet
recovery.
Regardless of the treatment administered, the time
to neutrophil engraftment was relatively fast in our
patients (median, 12 days). Further studies may be re-
quired to address the effect of linezolid on engraftment
in the setting of prolonged neutropenia (such as in
cord blood allografts) or prolonged exposure to line-
zolid (. 14 days).
This study is the largest series to date reporting on
the hematologic safety of linezolid in HSCT in
the early periengraftment period. Information on the
myelosuppressive potential of linezolid has significant
implications for physicians caring for patients
undergoingHSCTwith high rates of VRE colonization
and infection. At our institution, approximately
one-third of HSCT recipients are VRE carriers, and
one-third of VRE carriers subsequently develop VRE
bacteremia in the periengraftment period [4]. In our
study, we found no adverse effect on engraftment related
to linezolid treatment. Because of the low rates of hema-
tologic toxicity in thegeneral population, larger prospec-
tive studies are needed to fully determine the
hematologic safety of linezolid in patients undergoing
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